Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...

West Financial Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and ...

and points out that Catalent also contracts fill-and-finish services to Eli Lilly, currently its main rival in the GLP-1 ...